by Raynovich Rod | Aug 29, 2023 | 2020-21 Life Science Portfolios
Update-1 9/2 Biotechs nudge off bottom with IBB at 3 month high at $130 level. FTC concedes Amgen fight over Horizon deal. XBI finds an uptick of 2.44% to $81 handle on Friday. MedTech still sluggish with IHI in low fifties in choppy trading all year. Novartis joins...
by Rod Raynovich | Nov 21, 2022 | 2023 Rayno Biopharmaceuticals Portfolio
Update-1 11/22 Broad Market Rally with all major indices up over 1%. Small cap spec stocks gain momentum, XBI up 1.38%. Energy materials and tech strong. IBB up 0.79% to $134. Bears acknowledge year end strength but still say 2023 fraught with weakening economy and...
by Raynovich Rod | Aug 30, 2021 | 2020-21 Life Science Portfolios
Update-1 3:45P 9/1 FDA issues warning on JAK Inhibitor drug class. ABBV down 7%., PFE and LLY drugs also affected. Small cap rally intact: CRSP,CYRX, VCYT. Quidel (QDEL) up 5.45% on need for more COVID tests. ARKG and XBI up about 1.5%. Mid-caps all green. IBB up...
by Raynovich Rod | Jun 9, 2021 | 2023 Rayno Biopharmaceuticals Portfolio
Update 6/14 2p -EDT The ASCO Rally tailwind looks good whether you are a trader or long term investor. As we called it on May 31 we thought the timing was right to add positions to biotech stocks. The rally is a bit more spotty now after a ~10% + move in the XBI but...
by Raynovich Rod | Jan 13, 2021 | 2023 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
JPMorgan Healthcare Conference Notes #1: Current Portfolio Positions Focus is Coronavirus diagnostics and vaccines. Gene therapy is poised for next wave: The Conference boosted many stocks as you might expect in a bull market for biotech. We reviewed rather quickly...
by Raynovich Rod | Nov 4, 2019 | Biopharmaceuticals
Update-1 11/5 2p EST IBB flat, NAZ up 0.185, earnings from AMRN and REGN. Amarin down 3.5% to $16.83 on earnings but bulls are waiting for label expansion. Q3 Revenues are $112.4 M up 103%, increased prescriptions for Vascepa with a 12/28/19 PADUFA date. Regeneron...
by Raynovich Rod | Sep 18, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 A bit of a sell-off on end of week option expirations and cancellation of China visit to farm Bureau in MT. NAZ down 0.8%, S&P down 0.5%. Less reaction to China news now? Can biotech rally as contrian play to tech and industrials? tape in biotech was...
by Raynovich Rod | Apr 29, 2019 | Biopharmaceuticals
Large Cap Biopharma Stocks: Performance and Valuations for 2019. In 2019 the IBB was a less risky pick for a biopharma portfolio; ABBV and BMY look good. Merck (MRK) and Vertex (VRTX) were the top winners since 1/15/18. There was a severe correction in biopharma...
by Raynovich Rod | Apr 21, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 XLV up from bottom at $86 to $88.63. IBB holding but more choppy at $107 level. Update-2 12p EDT-IBB flattish at $106 as earnings on large caps come in-will be reviewed at end of week. ABBV down 0.8% on Humira concerns:, profit forecast raised EPS gains...
by Raynovich Rod | Apr 15, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-2 10:45a 4/17…XBI down 3.37% to FEB support at $86. Healthcare issues are spilling over to biotech.Red screen day and all biotechs hit very hard.Drug pricing models are under scrutiny. Update-1…NASDAQ ekes out small gains but large cap biotechs...